|
Apr 19
|
Hepion Pharmaceuticals Initiates Wind-Down Activities in Phase 2b ‘ASCEND-NASH’ Trial
|
|
Mar 6
|
Hepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael Purcell
|
|
Jan 3
|
Hepion Pharmaceuticals to Present at NASH-TAG 2024
|
|
Dec 7
|
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
|
|
Nov 28
|
Hepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development Summit
|
|
Nov 13
|
Hepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver Disease
|
|
Nov 10
|
Hepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of Rencofilstat
|